Fosamax Label Change to Add Warning for Femur Fractures
This has been a long time coming!
I have been actively involved in Fosamax litigation since 2006 and have lectured at numerous seminars on the subject. Back then, it was just osteonecrosis of the jaw (ONJ) on the radar. But soon after, a deeper, more ominous danger began to surface through internal Merck documents.
As my regular readers will remember, back in March 2010 and later in October 2010, I wrote publicly about the risk of Fosamax and femur fractures following the scrutiny of the ASBMR Task Force. The risk of femur fractures with Fosamax use comes on the heels of years of rock solid evidence that Fosamax also causes the terrible bone/jaw disorder ONJ. There is no other way to say it – Fosamax is simply a bad drug of the highest magnitude.
Today the FDA finally acted on the overwhelming evidence that long term use of Fosamax dramatically increases the risk of atypical, low energy and low trauma femur fractures. The risk of femur fractures has been added to the Warnings section of the Fosamax label. It is long overdue.
If you or someone you know has taken Fosamax and suffered a femur fracture or ONJ, please contact me directly for a free, no-obligation evaluation of your claim.
About the Firm: The Michael Brady Lynch Firm is a trial firm with a focus on pharmaceutical mass tort cases involving SSRI and Anti-Seizure Medication Birth Defects such as Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil, Depakote and Topamax, as well as Actos Bladder Cancer and Fosamax Femur Fractures, and medical device cases including DePuy Hip and Trans-Vaginal Mesh cases. Contact us today if you or someone you know has experienced side effects involving these products.